Expert Interview
A Second Look: Discussing the potential of UBT251, a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1, GIP and glucagon, recently acquired by Novo Nordisk
Ticker(s): NVO, LLYInstitution: University of Pittsburgh Medical Center
- Clinical Associate Professor of Medicine & Endocrinologist at UPMC
- Diabetes Clinical Unit Leader who sees 200+ patients with Type 1 Diabetes
- Clinical and Research Interest in diabetes technology and multidisciplinary modes of care
Can you provide some background information about yourself, your expertise, and your current practice setting?
Added By: ben_adminHow many patients with obesity do you currently see on a monthly basis?
Added By: ben_adminWhat is your opinion on the potential of the GLP-1 class for the treatment of pediatric obesity?
Added By: ben_adminWhat are your thoughts on the future usage of triple agonists, including UBT251 and Eli Lilly's retatrutide?
Added By: ben_adminWhat are the pros and cons to targeting GLP-1, GIP and glucagon?
Added By: ben_adminWhat is your excitement for UBT251 on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
